We have established an ex vivo mast cell degranulation assay carried out by incubating crude peritoneal exudate cells isolated from the mice, treated with a pharmacological agent of interest and administered anti-dinitrophenol (DNP) IgE beforehand, with DNP on a carrier protein.
Mast cell stabilizers are an essential part of allergy medication. Passive systemic anaphylaxis (PSA) is an animal assay widely used for investigating the effect of a pharmacological agent of interest on mast cells in vivo. As the anaphylactic symptoms are primarily attributed to exocytosis of the granules from mast cells, it is conceived that the agent to cause amelioration of the symptoms has a mast cell stabilizing activity. Despite the fact, it is prudent to confirm the activity by directly demonstrating the decline in the functional activity of mast cells following its treatment. In vitro degranulation assays using an immortalized mast cell line or cultured primary mast cells are routinely employed to that end. The results from the in vitro and in vivo assays may not always be akin to each other; however, as treatment conditions (e.g., treatment dose, time, surrounding environments) for the in vitro assays are often distinct from those for the in vivo assay such as PSA. In pursuit of an in vitro (or ex vivo) assay to reflect more closely the effect of a pharmacological agent on mast cells in vivo, we devised the ex vivo mast cell degranulation assay in which crude peritoneal exudate cells (PECs) isolated from the mice, treated with the agent and administered anti-dinitrophenol (DNP) IgE, were incubated directly with DNP on a carrier protein. It turned out that the assay was not only useful in validating the mast cell stabilizing activity of a pharmacological agent indicated by the in vivo assay but also practical and highly reproducible.
Mast cells play a central role in allergy1,2. When IgE located on the surface of mast cells via interaction with the high-affinity receptor for IgE (FcεRI) encounters a cognate allergen, a signaling cascade is elicited to prompt the release of the granules. As a result, a variety of allergy effector molecules, including monoamines (e.g., histamine, serotonin), cytokines (e.g., TNF-α), and proteolytic enzymes (e.g., tryptase, chymase), are released to cause a series of immunological, neurological and vasomuscular reactions3,4.
A class of pharmaceuticals is called mast cell stabilizer that alleviates the allergy symptoms by attenuating the mast cell function5. Passive systemic anaphylaxis (PSA) is an animal model often used for probing a mast cell stabilizing activity of pharmacological agents. As the anaphylactic symptoms result primarily from the activation of mast cells following interaction of passively transferred hapten-specific IgE with the hapten on a carrier protein injected into the animal later, it is well received that a pharmacological agent of interest bears a mast cell stabilizing activity when its treatment results in amelioration of the symptoms6. Still, it is often imperative to directly demonstrate impairment of the mast cell function by the agent in a separate experiment to rule out the possibility that improvement of the symptoms is derived from a mechanism other than suppression of mast cell function.
Mast cell degranulation assay, which is carried out by stimulating mast cells with a chemical reagent or a specific antigen of IgE forming a complex with FcεRI on the surface of mast cells to induce exocytosis of secretory granules (i.e., degranulation), is generally used for determining a mast cell stabilizing activity of a pharmacological reagent in vitro7. Several types of cells are used in that assay, including the rat basophilic leukemia (RBL) cell line8, bone marrow-derived mast cells (BMMC)9, and peritoneal cell-derived mast cells (PCMC)10. While useful as a large number of cells can be easily obtained, RBL is an immortalized cancer cell line whose cellular properties are no longer akin to those of mast cells in the body. Acquiring a sufficient number of BMMC or PCMC, even though their cellular properties may more closely resemble those of mast cells in the body, is often costly and time-consuming.
A degranulation assay using purified primary mast cells is a desirable alternative11. Nonetheless, the use of such an assay is not widespread as a facile method for purifying mast cells from animal tissue, particularly from mouse tissue, with a high yield, and purity is not yet available. Moreover, since the concentration and duration of treatment with a pharmacological agent to inhibit the mast cell function in vitro may not always coincide with those in vivo, results obtained with an in vitro degranulation assay may misrepresent those from an in vivo assay such as PSA, and vice versa. Hence, a novel degranulation assay, not only closely mimicking the way of mast cell activation transpiring in vivo but also accurately reflecting effects of a pharmacological reagent exerted on mast cells in vivo, is in high demand. In order to meet those needs, we devised an ex vivo mast cell degranulation assay where mast cells in peritoneal exudate cells (PECs) isolated from the mice, treated with a pharmacological agent of interest and administered IgE specific for dinitrophenol (DNP) beforehand, are stimulated with DNP-conjugated bovine serum albumin (BSA).
The finding that mast cell degranulation assay can be carried out with a relatively small number of crude mouse PECs is significant. Even though PECs must be an excellent source of primary mouse mast cells, it is demanding to purify mast cells in PECs. Although a density gradient media such as Percoll25 has been successfully used for purification of mast cells from rat PECs, its use for purification of mouse peritoneal mast cells has been limited presumably for the difference in the densities of r…
The authors have nothing to disclose.
We thank Mr. Wonhee Lee and Ms. Eunjoo Lee for their technical and administrative assistance. We also thank Dr. Thi Minh Nguyet Nguyen for her thoughtful comments. This work was supported by the research grants from Chungnam National University (CNU Research Grant 2017-2098-01) and from National Research Foundation of Korea (NRF-2019R1F1A1061894 and NRF-2019M3A9G4067293).
1 mL syringe | 1757589701 | ||
1.5 mL micro tube | Hisol | MT-15003 | |
10 mL syringe | 1757593161 | ||
15 mL conical tube | Thermo Fisher scientific | 14-959-53A | |
20xPBS | Tech & Innovation | BPB-9121-500mL | |
4-nitrophenyl-N-acetyl-β-D-glucosaminide | SIGMA | N9376 | |
5 mL polystyrene round-bottom tube | Life sciences | 352003 | |
50 mL conical tube | Thermo Fisher scientific | 14-959-49A | |
Aluminium Fiol | BioFact | TS1-3330 | |
Anti-mouse CD117(c-kit) | Biolegend | 135129 | keep at 2-8°C |
Anti-mouse IgE mAbs | Thermo Fisher scientific | 11-5992-81 | keep at 2-8°C |
Antiti-DNP-IgE | SIGMA | D8406-.2MG | keep at -20°C |
Centrifuge | HANIL | 396150 | |
D-(+)-gluouse | SIGMA | G8270 | |
Dexamethasone | SIGMA | D2915-100MG | |
DNP-BSA | Invitrogen | 2079360 | keep at -20°C |
EDTA | Biofact | PB131-500 | |
Fetal Bovine serum | Thermo Fisher scientific | 11455035 | |
Gelatin | SIGMA | G1890 | |
Glycine | JUNSEI | 27185-0350 | |
hemocytometer | ZEISS | 176045 | |
HEPES | Thermo Fisher scientific | 15630130 | |
Histamine ELISA kit | Abcam | GK3275957-4 | keep at 2-8°C |
Hotplate stirrer | Lab teach | zso-9001 | |
Isoflurance | Troikaa | I29159 | |
ketotifen fumarate salt | SIGMA | K2628 | |
MCPT-1 ELISA kit | Thermo Fisher scientific | 88-7503-22 | keep at 2-8°C |
Mouse Fc block | BD Biosciences | 553141 | keep at 2-8°C |
Propidium iodiole | SIGMA | 81845 | keep at 2-8°C |
RBC lysis buffer | Biolegend | 420301 | |
Round-bottom 96 well | SPL-life sciences | 30096 | |
Single use syringe filter | Startoriusag | 16555 | |
Streptavidin microbeads | MilteryiBiotec | 130-048-101 | keep at 2-8°C |
Triton X-100 | JUNSEIchemical | 49415-1601 | |
TWEEN 20 | SIGMA | 9005-64-5 | |
Water bath | CHANGSHINSCIENCE | 190107 |
.